| 2008 |
We aim to have nine clinical programmes in 2008
|
| September 2007 |
Outlicense of IP for CoVaccine HT™ adjuvant to Nobilon, a division of Schering Plough for use in its flu vaccines
|
| March 2007 |
Completion of manufacturing process scale up for CytoFab™ and receipt of £10 million milestone payment from AstraZeneca
|
| December 2006 |
Protherics’ raises £38 million to:
- acquire MacroMed Inc, a privately owned speciality drug development and manufacturing company based in the US for lead product OncoGel™ for the treatment of oesophageal and brain cancers
- in-license IP from Glenveigh Pharmaceuticals LLC for the use of DigiFab™ and GSK’s Digibind® in the treatment of pre-eclampsia and eclampsia
- in-license IP from Advanced In Vitro Cell Technologies for the use and co-development of acadesine in the treatment of B-cell chronic lymphocytic leukaemia (B-CLL)
|
June 2006
|
Acquisition of CoVaccine HT™ adjuvant from CoVaccine BV
|
| December 2005 |
Major licensing deal signed with AstraZeneca for the development and commercialisation of CytoFab™. Protherics is entitled to receive £195 million in upfront and milestone payments, in addition to payments for product supply and a 20% royalty on net global sales |
| |
| July 2005 |
Voraxaze™ Marketing Authorisation Application (MAA) submitted to EU regulatory agencies |
|
|
| September 2004 |
Transfer of the Porton Down research facility and out-licensing of early stage research acquired with Enact Pharma to two UK start-up companies |
| |
| July 2004 |
£9.3 million (net of expenses) Placing and Open Offer announced to fund a US and European sales and marketing function and manufacturing improvements |
| |
| June 2004 |
Maiden profits announced for the financial year which ended on the 31 March 2004 |
| |
| June 2003 |
Acquisition of Enact Pharma PLC and completion of a £3 million fundraising |
| |
| February 2002 |
US launch of DigiFab™, a treatment for the toxic effects of overdosage with the heart drug digoxin |
| |
| Spring 2001 |
US launch of CroFab™, the first new rattlesnake antivenom on the US market in 50 years |
| |
| September 1999 |
Protherics PLC was formed from the merger of Proteus International Plc and Therapeutic Antibodies Inc. |